Table 1 Demographic, clinical, and surgical characteristics of patients
Characteristic | Overall (n = 12) | Cohort 1 (n = 3) | Cohort 2 (n = 3) | Cohort 3 (n = 6) |
|---|---|---|---|---|
Age (years) | 56.8 (5.8) | 60.7 (5.1) | 54.3 (4.0) | 56.0 (6.7) |
Sex (male)—no. (%) | 8 (66.7%) | 2 (66.7%) | 3 (100.0%) | 3 (50.0%) |
KPS—no. (%) | ||||
 70 | 1 (8.3%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) |
 80 | 6 (50.0%) | 2 (66.7%) | 1 (33.3%) | 3 (50.0%) |
 90 | 5 (41.7%) | 1 (33.3%) | 1 (33.3%) | 3 (50.0%) |
MGMT promoter—no. (%) | ||||
 Methylated | 6 (50.0%) | 2 (66.7%) | 1 (33.3%) | 3 (50.0%) |
 Unmethylated | 6 (50.0%) | 1 (33.3%) | 2 (66.7%) | 3 (50.0%) |
IDH1/2—no. (%) | ||||
 Mutant | 4 (33.3%) | 1 (33.3%) | 1 (33.3%) | 2 (33.3%) |
 Wild-type | 8 (66.7%) | 2 (66.7%) | 2 (66.7%) | 4 (66.7%) |
 Time elapsed since the last radiotherapy session (weeks) | 66.5 (12.1) | 56.7 (8.1) | 73.3 (10.3) | 68 (12.9) |
 Median follow-up (months, IQR) | 17 (16–18) | 13 (12.5–14.5) | 16 (16–17) | 18 (18–18) |
Extent of resection in the last surgery—no. (%) | ||||
 GTR | 9 (75.0%) | 2 (66.7%) | 2 (66.7%) | 5 (83.3%) |
 IR | 2 (16.7%) | 1 (33.3%) | 1 (33.3%) | 0 (0.0%) |
 Biopsy | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (16.7%) |
Chemotherapeutic agent—no. (%) | ||||
 Temozolomide | 12 (100.0%) | 3 (100.0%) | 3 (100.0%) | 6 (100.0%) |
 Bevacizumab | 4 (33.3%) | 1 (33.3%) | 1 (33.3%) | 2 (33.3%) |
 Lomustine | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) |
Anatomical location—no. (%) | ||||
 Frontal | 5 (41.7%) | 2 (66.7%) | 1 (33.3%) | 2 (33.3%) |
 Temporal | 4 (33.3%) | 1 (33.3%) | 1 (33.3%) | 2 (33.3%) |
 Parietal | 1 (8.3%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) |
 Frontotemporal | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (16.7%) |
 Temporoparietal | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (16.7%) |